Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation and Depletion (2023 - 2025)

Historic Depreciation and Depletion for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $100000.0.

  • Compass Therapeutics' Depreciation and Depletion fell 5000.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 4285.71%. This contributed to the annual value of $600000.0 for FY2024, which is 1428.57% down from last year.
  • Compass Therapeutics' Depreciation and Depletion amounted to $100000.0 in Q3 2025, which was down 5000.0% from $100000.0 recorded in Q2 2025.
  • Compass Therapeutics' 5-year Depreciation and Depletion high stood at $200000.0 for Q1 2023, and its period low was $100000.0 during Q3 2023.
  • In the last 3 years, Compass Therapeutics' Depreciation and Depletion had a median value of $100000.0 in 2023 and averaged $145454.5.
  • Examining YoY changes over the last 5 years, Compass Therapeutics' Depreciation and Depletion showed a top increase of 10000.0% in 2024 and a maximum decrease of 5000.0% in 2024.
  • Over the past 3 years, Compass Therapeutics' Depreciation and Depletion (Quarter) stood at $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Its Depreciation and Depletion stands at $100000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $100000.0 for Q1 2025.